Daily Health Headlines

'Active Surveillance' of Prostate Cancer Doesn't Dampen Quality of Life

👤by HealthDay 0 comments 🕔Friday, July 29th, 2016

THURSDAY, July 28, 2016 (HealthDay News) -- Men with low-risk prostate cancer report a good quality of life after choosing active surveillance as a treatment for their disease, a new study finds.

Active surveillance for prostate cancer means a man chooses not to have surgery, radiation or chemotherapy, but instead follows a regular schedule of tests and exams to make sure the cancer isn't growing rapidly, the U.S. National Cancer Institute says.

The new study included 89 American men with low-risk prostate cancer and 420 men without the disease.

Over three years of follow-up, there were no significant differences between the two groups in health-related quality of life, according to the findings published in the Journal of Urology.

"To our knowledge, this is the first report of health-related quality-of-life outcomes of men on active surveillance for prostate cancer compared to men without prostate cancer in a prospective, multi-institutional study," lead investigator Dr. Christopher Porter said in a journal news release. He's from Virginia Mason Medical Center in Seattle.

"Our results suggest that for at least three years, men selecting active surveillance do not experience a substantial psychological burden or clinically significant problems due to untreated disease," he added.

Most men with prostate cancer have low-risk disease and must make the difficult decision between having their cancer monitored or receiving treatment. But treatments carry the risk of side effects, such as urinary, bowel and sexual dysfunction, the study authors noted.

"The potential clinical impact of these results is significant and will allow clinicians to counsel patients effectively in regard to the potential health-related quality-of-life outcomes associated with active surveillance," Porter said.

-- Robert Preidt

Article Credits / Source

HealthDay

HealthDay provides up to the minute breaking health news. Click here to view this full article from HealthDay.

SOURCE: Journal of Urology, news release, July 25, 2016

View More Articles From HealthDay 🌎View Article Website

Sponsored Product

Lunar Sleep for $1.95

Lunar Sleep for $1.95

People who have trouble sleeping typically have low levels of melatonin, so melatonin supplements seem like a logical fix for insomnia. There is a high demand for sleep aids, especially in the U.S. The National Health Interview Survey done in 2002, and again in 2007, found 1.6 million US adults were using complementary and alternative sleep aids for insomnia. Lunar Sleep was a top choice. Use Promo Code: Sleep2014 and only pay $1.95 S&H.

Get Lunar Sleep for $1.95

More Cancer Articles

No Benefit From Routine Thyroid Cancer Screening: Task Force

No Benefit From Routine Thyroid Cancer Screening: Task Force0

TUESDAY, Nov. 22, 2016 (HealthDay News) -- Doctors should not screen for thyroid cancer in patients who have no symptoms of the disease, according to a U.S. Preventive Services Task Force draft recommendation. It reaffirms a recommendation ...

Depressed Women Less Likely to Get Best Breast Cancer Care: Study

Depressed Women Less Likely to Get Best Breast Cancer Care: Study0

FRIDAY, Nov. 18, 2016 (HealthDay News) -- Breast cancer patients with a history of depression are less likely to receive recommended care for their disease, a new study finds. The study included more than 45,000 Danish women diagnosed with ...

Earnings Fall After a Child's Cancer Diagnosis

Earnings Fall After a Child's Cancer Diagnosis0

MONDAY, Nov. 21, 2016 (HealthDay News) -- After a child's cancer diagnosis, parents' income often drops and mothers frequently stop working, a new study finds. Moreover, the financial effects of a cancer diagnosis can last years, with mothers' ...

Monoclonal Antibodies

Monoclonal Antibodies0

home / cancer center / cancer a-z list / monoclonal antibodies index / monoclonal antibodies drug monograph Pharmacy Author: Omudhome Ogbru, PharmD Omudhome Ogbru, PharmDDr. Ogbru received his ...

New Drug May Brighten Outlook for Advanced Breast Cancer

New Drug May Brighten Outlook for Advanced Breast Cancer0

WEDNESDAY, Nov. 16, 2016 (HealthDay News) -- A recently approved drug can help slow the progression of advanced breast cancer, a new clinical trial confirms. The drug, called palbociclib (Ibrance), was approved in the United States last year ...

View More Cancer Articles

0 Comments

Write a Comment

Your email address will not be published. Required fields are marked *

Our Mailing List

Subscribe to our mailing list to get the latest health news as it breaks!

Your information will not be shared with anyone!